文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-氟雌二醇(18F-FES)PET/CT指导HR+/HER2-转移性乳腺癌一线治疗:对无进展生存期的影响

18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-07-19

该回顾性研究纳入473例HR+/HER2-转移性乳腺癌患者,其中156例在一线治疗前接受18F-FES PET/CT筛查。在CDK4/6抑制剂联合内分泌治疗队列中,FES筛查组的中位无进展生存期为32.4个月,未筛查组为17.3个月(HR=0.49,95%CI 0.34-0.69,p<0.0001);在化疗队列中,筛查组的中位无进展生存期为11.38个月,未筛查组为8.91个月(HR=0.56,95%CI 0.33-0.94,p=0.026)。

要点

  • 在CDK4/6抑制剂联合内分泌治疗队列中,FES筛查组的中位无进展生存期为32.4个月,未筛查组为17.3个月(HR=0.49,p<0.0001)。
  • 在化疗队列中,FES筛查组的中位无进展生存期为11.38个月,未筛查组为8.91个月(HR=0.56,p=0.026)。
  • 全FES阳性转移灶患者中111例和FES异质性患者中17例接受了CDK4/6抑制剂联合内分泌治疗。

核心结论

  • 接受FES指导初始治疗的HR+/HER2-转移性乳腺癌患者,疗效显著优于未接受18F-FES PET/CT评估的患者。
  • 该回顾性研究强调,在给予一线治疗前进行FES评估对评价ER表达具有关键指导作用。
  • 在本研究中,对新诊断的HR+/HER2-转移性乳腺癌患者,采用18F-FES PET指导一线治疗时观察到无进展生存期改善。

研究设计与样本

  • 回顾性研究,筛选2020年至2024年复旦大学附属肿瘤医院的1613例HR+/HER2-转移性乳腺癌患者,纳入473例接受标准一线治疗的患者。

主要发现

  • 156例(33.0%)在一线治疗前接受18F-FES PET筛查,317例(67.0%)未筛查。
  • 在CDK4/6抑制剂联合内分泌治疗队列中,FES筛查组的中位无进展生存期为32.4个月,未筛查组为17.3个月(HR=0.49,95%CI 0.34-0.69,p<0.0001)。
  • 在化疗队列中,FES筛查组的中位无进展生存期为11.38个月,未筛查组为8.91个月(HR=0.56,95%CI 0.33-0.94,p=0.026)。

关键数值与推荐

  • 全FES阳性转移灶患者111例和FES异质性患者17例接受了CDK4/6抑制剂联合内分泌治疗。
  • 全FES阴性转移灶患者21例和FES异质性患者7例接受了化疗。
  • 未筛查组中,236例接受了CDK4/6抑制剂联合内分泌治疗,81例接受了化疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i+ET) have revolutionized treatment for HR+/HER2- metastatic breast cancer (MBC), inter-lesional estrogen receptor (ER) heterogeneity limits therapeutic efficacy in a subset of patients. Whole-body 18F-fluoroestradiol (18F-FES) PET/CT enables non-invasive ER quantification across all metastatic sites. However, whether 18F-FES-guided therapy selection improves clinical outcomes in relatively large sample cohorts is not yet well-established. PATIENTS AND METHODS: We screened all 1613 HR+/HER2- metastatic breast cancer (MBC) patients from 2020 to 2024 at Fudan University Shanghai Cancer Center. Patients who received standard first line treatment were enrolled in this retrospective study. RESULTS: A total of 473 patients were included in the study. 156(33.0%) and 317 (67.0%) patients were screened or unscreened by 18F-FES-PET before first-line treatment. 111 patients with all-FES positive metastatic lesions and 17 patients with FES heterogeneity received CDK4/6 inhibitors combined with endocrine therapy. 21 patients with all-FES negative metastatic lesions and 7 patients with FES heterogeneity received chemotherapy (CT). As for the unscreened group, 236 received CDK4/6 inhibitors combined with endocrine therapy and 81 received CT. In CDK4/6 inhibitors combined with endocrine therapy cohort, FES-screened group showed a significantly prolonged progression-free survival (PFS) compared with unscreened group (mPFS 32.4 months versus 17.3 months, Hazard Ratio = 0.49; 95% CI, 0.34 to 0.69; p < 0.0001). And chemotherapy cohort showed superior PFS for screened patients as well (mPFS 11.38 months versus 8.91 months, Hazard Ratio = 0.56; 95% CI, 0.33 to 0.94; p = 0.026). CONCLUSIONS: HR + /HER2- MBC patients with FES-guided initial treatment showed significantly better efficacy than those who had not been assessed by 18F-FES-PET/CT. This retrospective study highlights the crucial instructive role of FES assessment in evaluating ER expression in patients prior to administering first-line treatment. In the present study, improved PFS was observed when first-line therapy was guided by 18F-FES-PET in newly diagnosed HR+/HER2- MBC patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Xie Y, Chen Y, Liu C, et al. 18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival. Eur J Nucl Med Mol Imaging. 2025. PMID: 40682675. doi:10.1007/s00259-025-07459-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。